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Abstract
Background: It is presently well accepted that the breast exhibits a circadian rhythm reflective of its
physiology. There is increasing evidence that rhythms associated with malignant cells proliferation are
largely non-circadian. Cancer development appears to generate its own thermal signatures and the
complexity of these signatures may be a reflection of its degree of development. The limitations of
mammography as a screening modality especially in young women with dense breasts necessitated the
development of novel and more effective screening strategies with a high sensitivity and specificity. The
aim of this prospective study was to evaluate the feasibility of dynamic thermal analysis (DTA) as a potential
breast cancer screening tool.
Methods: 173 women undergoing mammography as part of clinical assessment of their breast symptoms
were recruited prior to having a biopsy. Thermal data from the breast surface were collected every five
minutes for a period of 48 hours using eight thermal sensors placed on each breast surface [First Warning
System (FWS), Lifeline Biotechnologies, Florida, USA]. Thermal data were recorded by microprocessors
during the test period and analysed using specially developed statistical software. Temperature points from
each contra-lateral sensor are plotted against each other to form a thermal motion picture of a lesion's
physiological activity. DTA interpretations [positive (abnormal thermal signature) and negative (normal
thermal signature)] were compared with mammography and final histology findings.
Results:  118 (68%) of participating patients, were found to have breast cancer on final histology.
Mammography was diagnostic of malignancy (M5) in 55 (47%), indeterminate (M3, M4) in 54 (46%) and
normal/benign (M1, M2) in 9 (8%) patients. DTA data was available on 160 (92.5%) participants. Using our
initial algorithm, DTA was interpreted as positive in 113 patients and negative in 47 patients. Abnormal
thermal signatures were found in 76 (72%) out of 105 breast cancer patients and 37 of the 55 benign cases.
Then we developed a new algorithm using multiple-layer perception and SoftMax output artificial neural
networks (ANN) on a subgroup (n = 38) of recorded files. The sensitivity improved to 76% (16/21) and
false positives decreased to 26% (7/27)
Conclusion: DTA of the breast is a feasible, non invasive approach that seems to be sensitive for the
detection of breast cancer. However, the test has a limited specificity that can be improved further using
ANN. Prospective multi-centre trials are required to validate this promising modality as an adjunct to
screening mammography especially in young women with dense breasts.
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Introduction
Breast cancer continues to be the most common malig-
nancy in women. Epidemiological studies estimate that
one in eight women will develop breast cancer during
their lifetimes [1-4]. Moreover, one in five women with
breast cancer will die of the disease despite the considera-
ble advances in treatment. Given these circumstances,
early detection of breast cancer is considered an important
prognostic factor, and Reidy has aptly suggested that
death from malignancy rather than its detection should be
the point of reference in evaluating any screening pro-
gramme [5].
Currently, mammography is considered the gold standard
as a screening tool for the early detection of breast cancer.
Unfortunately, it is a standard that does not always shine
brightly in that wide variations exist in its sensitivity and
specificity in published reports, as evidenced by a recent
review by Sobti et al [6]. Moreover, it's limitations in
young and premenopausal women with dense breast tis-
sue strengthen the need to develop new modalities for the
early detection of breast cancer, especially in this group of
vulnerable patients. To this end, magnetic resonance
imaging (MRI) has been shown to be more sensitive in the
early detection of occult breast cancers, particularly in pre-
menopausal women for whom the sensitivity of mam-
mography is compromised [7] but with less specificity [8].
Additional modalities are still under development such as
electrical impedance scanning (EIS) [9], mammary duc-
toscopy (MD) and proteomics of nipple aspirate fluid
(NAF) and serum [10,11].
The establishment and growth of most tumours depend
on the successful recruitment of new blood vessels into
and around the tumour cells. This latter process, also
known as angiogenesis, is dependent on the production
of angiogenic growth factors by the tumour cells [12].
Because these new vessels lack smooth muscle fibers ren-
dering them unreceptive to control by epinephrine
[13,14], a more constant blood flow to the area increases
the local temperature in the area surrounding the tumor.
It is now recognised that the breast exhibits a circadian
rhythm that is reflective of its physiology [1,14]. The rela-
tionship between breast skin temperature and breast can-
cer was thoroughly examined by Gros et al [15,16]. The
investigators found that the differences between the char-
acteristics of rhythmic changes in skin temperature of clin-
ically healthy and cancerous breasts were real and
measurable.
The superficial thermal patterns measured on the surface
of the breast are most likely related to tissue metabolism
and vascularization within the underlying tissue. Such
thermal patterns change significantly as a result of normal
phenomena including the menstrual cycle, pregnancy
and, more importantly, the pathologic process itself.
Additionally, It is generally stated that cancer develop-
ment, in most instances, represents the summation of
large number of mutations that occur over years, each
with its own particular histologic phenotype that can be
seen in pre-menopausal mastectomy specimens [17-21].
Cancer development appears to generate its own thermal
signatures, and the complexity or lack thereof may be a
reflection of its degree of development [22-26].
Based on the understanding of the above pathological
observations and the recent technological advances that
have facilitated the recording of circadian rhythm varia-
tions of the breast[14] we prospectively aimed to examine
the feasibility of a new potential screening method called
the dynamic thermal analysis (DTA) for breast cancer
detection.
Thermal sensors of FWS applied to both breasts Figure 1
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Methods and materials
Women referred to a private mammography unit in La
Plata, Argentina as part of their clinical assessment for
breast symptoms were recruited prior to having an indi-
cated or otherwise planned biopsy. Institutional guide-
lines, including ethical approval and informed consent,
were followed.
Thermal data from the breast surface were collected every
five minutes for a period of 48 hours using eight thermal
sensors placed on each breast surface [First Warning Sys-
tem (FWS), Lifeline Biotechnologies, Florida, USA]. Sen-
sors are placed in anatomically critical positions elicited
by data obtained from clinical examination and mam-
mography as to where suspected cancers are located (Fig-
ure 1). Thermal data were recorded by microprocessors
during the test period. More than 500 readings were col-
lected in each patient. These data were analysed using spe-
cially developed statistical software called artificial neural
networks (ANN). Temperature points from each contra-
lateral sensor were plotted against each other to form a
thermal motion pattern of a lesion's physiological activity
(Figure 2, 3)
DTA interpretations [positive (abnormal thermal signa-
ture) and negative (normal thermal signature)] were com-
pared with mammography and final histology findings.
Results
A total of 173 women underwent mammography; their
median age was 56 years (range: 17–85 Years). Fifty-eight
women had a family history of breast cancer: 98 patients
(56.6%) had a breast lump palpable of which 38 patients
had a family history of breast cancer (38.7%)One hun-
DTA in a patient with T1 breast cancer Figure 2
DTA in a patient with T1 breast cancer.
DTA in a patient with a fibroadenoma Figure 3
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dred and eighteen (68%) of the 173 participating patients
were found to have breast cancer on final histology with a
tumour size range of 4–60 mm.
Mammography was diagnostic of malignancy (M5) in 55
patients (47%), indeterminate (M3, M4) in 54 patients
(46%) and normal or benign (M1, M2) in 9 (8%)
patients. (Table 1). Thermal data obtained from the breast
surface were analysed in 160 participants (92.5%) using
an initial algorithm. These data were interpreted as posi-
tive in113 patients and negative in 47 patients. Abnormal
thermal signatures were found in 76 (72%) out of 105
breast cancer patients and 37 of the 55 benign cases
(67%) (Specificity 32%) (Table 2)
We then developed a new algorithm using the multi-layer
perception (MLP) with soft max output artificial neural
networks (ANN) for use on a subgroup of participants (n
= 38). MLP correctly detected cancer in 16 patients out of
21 participants improving the sensitivity to 76%. Further-
more, false positive cases were decreased to 26% (only 7
patients out of 27) increasing the specificity to 74%.
Discussion
Currently mammography is the best available approach
for the early detection of breast cancer in the general pop-
ulation with a sensitivity of 75–90% [2]. However, the
positive predictive value is only 25% [3,4]. It is interesting
to mention that 25–30% of breast cancers are found in
pre-menopausal women. DTA is a safe and non-invasive
technique that offers the advantage of providing informa-
tion on the physiology of the breast, specifically the super-
ficial thermal patterns that can be measured on the surface
and relate to tissue metabolism and vascularization
within the underlying tissue.
In healthy breasts, heat conductivity is constant in most
cases and generally can be characterized in terms of circa-
dian rhythm periodicity [27]. In contrast, the rhythms
associated with malignant cells proliferation are largely
non circadian and suggest that a circadian to ultradian
shift may be a general correlation to neoplasia [14]. Due
to the increased blood flow and the lack of receptivity in
the newly formed vessels in malignancy, temperature pro-
duction exhibits circadian rhythmic variations to a far
lesser degree than is evident in the healthy breasts [13].
Our study demonstrates that 72% of patients with breast
cancer have non circadian changes of the breast thermal
patterns. However, the initial specificity of the test was
very low. We then used the artificial neural network
(ANN) to analyse the thermal data recorded in order to
improve the sensitivity and specificity. In this type of anal-
ysis, the network learns by itself from a set of example
solutions. It could also be divided into a supervised and
unsupervised learning phase. The modification of the ini-
tial algorithm into a multi-layer perception (MLP) with
soft max output artificial neural networks resulted in an
increased sensitivity and specificity of the test. This new
algorithm needs to be evaluated further in prospective
multi-centre trials to validate these promising observa-
tions.
Appreciation of the clinical usefulness of heat-sensing
devices in breast cancer has suffered because of poorly
conceived attempts to exploit their diagnostic potential.
Little attention has been paid to the thermal signal being
an expression of immensely complicated biologic func-
tions. The issue of false positives is still unclear; it may
reflect an abnormality that can not be detected by conven-
tional methods. The presence of non circadian rhythm in
the absence of mammographic or clinical evidence of can-
Table 1: Mammography findings
TEST DISEASE
Cancer Present 118 Cancer Absent 55
Mammogram True Positive 55 47% True Negative 32 58%
False Negative 9 8% False Positive 7 13%
Indeterminate 54 46% Indeterminate 16 29%
Table 2: Results of the initial DTA
TEST Cancer Patients Cancer absent
DTA True Positive 76 72% True Negative 18 33%
False Negative 29 28% False Positive 37 67%Publish with BioMed Central    and   every 
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cer does not preclude the presence of cancer in its very
early stages. Patients with such signs might be considered
high risk for breast cancer which may become clinically
evident at a later date. This is supported by a previous
French study investigating the long term follow up of indi-
viduals who had abnormal thermal signs in the absence of
physical or mammographic findings [15]. However, fur-
ther work is needed to evaluate this hypothesis.
The current DTA study has some other limitations. The
ANN requires 540 input data for reliable analysis. Ther-
mal data require a long time to be recorded (48 hours),
and this may be considered as a downside of this technol-
ogy. We are in the process of developing a new monitor
which records thermal data every 5 seconds thus reducing
the test time significantly.
If future validation studies confirm the reliability of DTA,
then it can be used as an adjunct to mammography, espe-
cially in pre-menopausal women with dense breasts.
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